Greenwich, CT – According to filings with the U.S. Securities and Exchange Commission, Oncosynergy is raising $5,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Anne-Marie Carbonell played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Oncosynergy

OncoSynergy is a patient-focused biotechnology startup spun out from UCSF and the JLABS South San Francisco incubator. Based in beautiful Greenwich, Connecticut, we are creating a new class of cancer medicines to maximize patient survival and quality of life with minimal side effects. We are a small, nimble startup team preparing to launch our first clinical trial in 2019 for glioblastoma.

To learn more about Oncosynergy, visit http://oncosynergy.com/

Contact:
Anne-Marie Carbonell, Chief Executive Officer
415-299-4249
https://www.linkedin.com/in/anne-marie-carbonell-md-62b85378/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved